Business
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency1, and Core EBITDA2 of 1.211 billion USD, Growing 18.9% at Constant Currency
ZUG, Switzerland, March 05, 2026--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025.
About this update from Galderma Group Ag
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":823,"height":209,"url":"https://media.zenfs.com/en/business-wire.com/634285f28bd6dc06e9b464bc3666df98"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/F4r_mpA7aw4PXA8xGew5Uw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI0NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/634285f28bd6dc06e9b464bc3666df98","width":823,"height":209},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/1BMJyho.mFLfFwjHryhYKQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE2NDY7aD00MTg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/634285f28bd6dc06e9b464bc3666df98","width":823,"height":209}},"lazy":false},{"type":"text","content":"Ad hoc announcement pursuant to Art. 53 LR","length":42,"tagName":"p"},{"type":"text","content":"ZUG, Switzerland, March 05, 2026--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025.","length":185,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume.","length":194,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Broad-based net sales growth, growing double-digits in both International markets and the U.S.","length":94,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency.","length":220,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new product launches across Galderma’s full portfolio of flagship brands.","length":375,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Significant progress and strategic investments across a robu...